摘要
目的 观察他克莫司 (FK5 0 6 )替换环孢素A(CsA)治疗肾移植后肝、肾功能损害的有效性及安全性。方法 将 6 1例肾移植后肝、肾功能异常的患者分为 :肝损害组 (Ⅰ组 ,2 3例 )、肾损害组(Ⅱ组 ,2 0例 )及肝、肾均损害组 (Ⅲ组 ,18例 )。观察用FK5 0 6替换CsA 12个月后各组患者肝、肾功能变化情况及药物的不良反应。结果 用FK5 0 6替换CsA 12个月后 ,Ⅰ组中 87.8%的患者明显恢复 ,Ⅱ组中 6 5 .8%明显恢复 ,而且替换期间未出现急性排斥反应。主要不良反应为血糖升高、震颤等 ,经对症治疗及调整FK5 0 6药量后症状均缓解。结论 用FK5 0 6替换CsA是治疗肾移植后肝、肾功能损害的一种安全而有效的措施。
Objective To evaluate the therapeutic efficacy and safety of CsA substituted by tacrolimus (FK506) in renal allograft recipients with hepatic and/or renal dysfunction.Methods 61 cases of renal allograft recipients with hepatic and/or renal dysfunction were divided into three groups: hepatic dysfunction group (Ⅰ,n=23), renal dysfunction group (Ⅱ,n=20), hepatic and renal dysfunction group (Ⅲ,n=18). The changes of hepatic and renal funtion and side effects of FK506 were observed for 12 months in all the patients. Results After 12 months, about 87.8?% of the recipients with hepatic dysfunction and 65.8?% of the recipients with renal dysfunction recovered obviously. No acute rejection occurred during conversion. Hyperglycemia and upper limbs trembling were main side effects. All the side effects restored by appropriate management and adjustment of dose of FK506.Conclusion FK506 substituting for CsA is an effective and safe measure in treating hepatic and/or graft dysfunction which occurred in renal allograft recipients.
出处
《中华器官移植杂志》
CAS
CSCD
北大核心
2003年第2期119-120,共2页
Chinese Journal of Organ Transplantation
